**SUPPLEMENTARY MATERIAL**

**Incidence trends in ischaemic and non-ischaemic heart failure in people with and without type 2 diabetes, 2000-2019: an observational study in England**

**Contents**

[**Table S1: Missing data at baseline** 2](#_Toc174891015)

[**Figure S1: CPRD Aurum flowchart diagram** 3](#_Toc174891016)

[**Figure S2: CPRD GOLD flowchart diagram** 4](#_Toc174891017)

[**Figure S3: Sex-stratified age-standardised 10-year incident rates of heart failure by year at type 2 diabetes diagnosis, deprivation and diabetes status** 5](#_Toc174891018)

[**Figure S4: Sex-stratified 10-year incident rates of heart failure (inpatient or death) by year at type 2 diabetes diagnosis and diabetes status** 6](#_Toc174891019)

[**Figure S5: Sex-stratified 10-year incident rates of heart failure by year at type 2 diagnosis and diabetes status, with prevalent ischaemic heart disease at study entry** 7](#_Toc174891020)

[**Figure S6: Sex-stratified 5-year incident rates of heart failure by year at type 2 diabetes diagnosis and diabetes status** 8](#_Toc174891021)

[**RECORD CHECKLIST**  9](#_Toc174891022)

# **Table S1: Missing data at baseline**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total**  **(N = 735,810)** | | **People with T2D**  **(n = 214,975)** | | **People without diabetes**  **(n = 520,835)** | |
|  | **Missing (n)** | **Missing (%)** | **Missing (n)** | **Missing (%)** | **Missing (n)** | **Missing (%)** |
| Total cholesterol | 340,617 | 46.29 | 54,964 | 25.57 | 285,653 | 54.85 |
| Alcohol intake status | 126,869 | 17.24 | 34,346 | 15.98 | 92,523 | 17.76 |

Missing data at baseline (index date) for total cholesterol and alcohol intake status in the cohort of individuals without missing data on ethnicity, IMD, systolic blood pressure, smoking status, BMI (Figure S1 and S2).

# **Figure S1: CPRD Aurum flowchart diagram**

A black and grey screen with a black text

Description automatically generated

**CPRD Aurum participants (without prevalent heart failure)  
from 1st January 2000 until 29th March 2021   
 N = 2,174,776 (T2D = 668,679; without diabetes = 1,506,097)**

N = 920,214   
(T2D = 226,242; without diabetes = 693,972)

N = 919,176  
(T2D = 226,242; without diabetes = 692,934)

Excluded CVD (MI, IHD, stroke, angina, PVD) at or prior to index date; n = 137,922

N = 1,058,136   
(T2D = 282,527; without diabetes = 775,609)

Excluded those with an index date after 2009;

n = 1,116,640

Excluded those prescribed glucose-lowering drugs and without diabetes;

n = 1,038

**N = 538,246   
(T2D = 158,938; without diabetes = 379,308)**

Abbreviations: BMI = body mass index, BP = blood pressure, CPRD = clinical practical research datalink, CVD = cardiovascular disease, IHD = ischaemic heart disease, IMD = index of multiple deprivation, N = total number of people, PVD = peripheral vascular disease, T2D = type 2 diabetes.

# **Figure S2: CPRD GOLD flowchart diagram**

A black screen with a black text

Description automatically generated

**N = 197,564  
(T2D = 56,037; without diabetes = 141,527)**

**CPRD GOLD participants (without prevalent heart failure)  
from 1st January 2000 until 29th March 2021   
N = 668,903 (T2D = 201,820; without diabetes = 467,083)**

N = 296,921  
(T2D = 73,098; without diabetes = 223,823)

N = 296,785  
(T2D = 73,098; without diabetes = 223,687)

Excluded CVD (MI, IHD, stroke, angina, PVD) at or prior to index date; n = 69,468

Excluded those prescribed glucose-lowering drugs and without diabetes;

n = 136

N = 366,389  
(T2D = 100,118; without diabetes = 266,271)

Excluded those with an index date after 2009; n = 302,514

Abbreviations: BMI = body mass index, BP = blood pressure, CPRD = clinical practical research datalink, CVD = cardiovascular disease, IHD = ischaemic heart disease, IMD = index of multiple deprivation, N = total number of people, PVD = peripheral vascular disease, T2D = type 2 diabetes.


# **Figure S3: Sex-stratified age-standardised 10-year incident rates of heart failure by year at type 2 diabetes diagnosis, deprivation and diabetes status**

**A graph of different colored lines

Description automatically generated with medium confidence**


Abbreviations: T2D = type 2 diabetes. Age-standardised rates at mean total population age (60 years). Bars indicate 95% confidence intervals. Quintile 1: least deprived; quintile 5, most deprived (Index of Multiple Deprivation).

# **Figure S4: Sex-stratified 10-year incident rates of heart failure (inpatient or death) by year at type 2 diabetes diagnosis and diabetes status**

****

Abbreviations: T2D = type 2 diabetes. Age-standardised rates at mean total population age (60 years). Bars indicate 95% confidence intervals. Dashed lines are estimates from the main analysis (Figure 1).

# **Figure S5: Sex-stratified 10-year incident rates of heart failure by year at type 2 diagnosis and diabetes status, with prevalent ischaemic heart disease at study entry**

****

Abbreviations: T2D = type 2 diabetes. Age-standardised rates at mean total population age (60 years). Bars indicate 95% confidence intervals. Dashed lines are estimates from the main analysis (Figure 1).

# **Figure S6: Sex-stratified 5-year incident rates of heart failure by year at type 2 diabetes diagnosis and diabetes status**

A group of graphs showing different colors

Description automatically generated with medium confidence

Abbreviations: T2D = type 2 diabetes. Age-standardised rates at mean total population age (60 years). Bars indicate 95% confidence intervals. Dashed lines are estimates from the main analysis (Figure 1).

# **RECORD CHECKLIST**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Item No.** | **STROBE items** | **Location in manuscript where items are reported** | **RECORD items** | **Location in manuscript where items are reported** |
| **Title and abstract** | | | | | |
|  | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1-2 | RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.  RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract. | 1-2  1-2  1-2 |
| **Introduction** | | | | | |
| Background rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 3 |  |  |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 3 |  |  |
| **Methods** | | | | | |
| Study Design | 4 | Present key elements of study design early in the paper | 444 4 |  |  |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4 |  |  |
| Participants | 6 | *(a) Cohort study* - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  *(b) Cohort study* - For matched studies, give matching criteria and number of exposed and unexposed | 4  4 | RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.    RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage. | Page 4 Figure S1  Figure S2  4  4 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | 4-5 | RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided. | 4-5 |
| Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group | 5 |  |  |
| Bias | 9 | Describe any efforts to address potential sources of bias | 4-6 |  |  |
| Study size | 10 | Explain how the study size was arrived at | 4-5; Figure S1; Figure S2 |  |  |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why | 5-6 |  |  |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding  (b) Describe any methods used to examine subgroups and interactions  (c) Explain how missing data were addressed  (d) *Cohort study* - If applicable, explain how loss to follow-up was addressed  (e) Describe any sensitivity analyses | 5-6  5-6  5-6  5-6  5-6 |  |  |
| Data access and cleaning methods |  | .. |  | RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.  RECORD 12.2: Authors should provide information on the data cleaning methods used in the study. | 12  6 |
| Linkage |  | .. |  | RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided. | 4 |
| **Results** | | | | | |
| Participants | 13 | (a) Report the numbers of individuals at each stage of the study (*e.g.*, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed)  (b) Give reasons for non-participation at each stage.  (c) Consider use of a flow diagram | Figure S1  Figure S2  Page 7 | RECORD 13.1: Describe in detail the selection of the persons included in the study (*i.e.,* study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram. | Figure S1  Figure S2 |
| Descriptive data | 14 | (a) Give characteristics of study participants (*e.g.*, demographic, clinical, social) and information on exposures and potential confounders  (b) Indicate the number of participants with missing data for each variable of interest  (c) *Cohort study* - summarise follow-up time (*e.g.*, average and total amount) | 7  Figure S1; Figure S2  7-8 |  |  |
| Outcome data | 15 | *Cohort study* - Report numbers of outcome events or summary measures over time | Table 2 |  |  |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included  (b) Report category boundaries when continuous variables were categorized  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Table 2  Page 7-9  Table 2 Page 7-9  Table 2; Page 7-9 |  |  |
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | 9 |  |  |
| **Discussion** | | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 10-11 |  |  |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 11 | RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported. | 10-11 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 10-12 |  |  |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 10-12 |  |  |
| **Other Information** | | | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 12 |  |  |
| Accessibility of protocol, raw data, and programming code |  | .. |  | RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code. | 4 |

Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The Reporting of studies Conducted using Observational Routinely collected health Data (RECORD) Statement. https://doi.org/10.1371/journal.pmed.1001885

Page numbers refer to the original submission.